Document is current

Any future updates will be listed below

Clinical outcomes of first line FOLFIRINOX vs. gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System

Crossref DOI link: https://doi.org/10.21037/jgo-21-202

Published Online: 2021-12

Published Print: 2021-12

Update policy: https://doi.org/10.21037/ame_crossmark_policy

About CrossMark